Peripheral T Cell Lymphoma, Unspecified
3
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Chemotherapy
Research Leaders
10 sponsors active, led by Yonsei University
Related Conditions
Often studied with 12 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
33%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Research Network
Common Treatments
- Chemotherapy1
- Alemtuzumab1
- Anti Cd30 Cart Cell Injection1
Active Sponsors
- Yonsei University1
- Asan Medical Center1
- Nordic Lymphoma Group1
- Samsung Medical Center1
- Korea Cancer Center Hospital1
Top Investigators
First Affiliated Hospital of Zhejiang University
Samsung Medical Center
University of Göttingen
Related Conditions
- Gray Zone Lymphoma1
- Hodgkin Lymphoma1
- Nkt Cell Lymphoma1
- Extranodal Nktcell Lymphoma1
- Anaplastic Large Cell Lymphoma1